DewBerry Joins Benaroya Research Institute Board of Directors

Seattle, WA

SEATTLE - (Feb. 18, 2009) - Benaroya Research Institute at Virginia Mason (BRI) announced the appointment of Carla DewBerry to its Board of Directors.

“Carla’s experience in financial and legal matters brings a unique perspective to BRI’s board of directors,” said Gerald Nepom, MD, PhD, director of BRI. “With her and the other board members’ guidance, BRI will continue to be a leader in scientific innovation and advancement that improves lives.”

DewBerry is an attorney with Garvey Schubert Barer in Seattle. She specializes in general corporate law, health-care law with an emphasis in regulatory compliance and investigations/audits and regulatory defense representation. She was cited as one of The Best Lawyers in America in the specialty of health-care law in 2007. DewBerry is active in her community and currently serves on the Capitol Hill Housing Improvement Program (CHHIP) board of directors and the Tobacco Settlement Authority.

DewBerry practiced with Bennett Bigelow & Leedom, P.S. in Seattle from 1986 to 2007. Prior to that, she was a tax manager with Arthur Anderson in San Francisco and Seattle. She completed her juris doctorate degree at UC Berkeley School of Law and attended the University of San Francisco for her undergraduate work.

About Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI), founded in 1956, is an international leader in immune system and autoimmune disease research translating discoveries to real-life applications. Autoimmune disease happens when the immune system, designed to protect the body, attacks it instead. BRI is one of the few research institutes in the world discovering causes and cures to eliminate autoimmune diseases such as Type 1 diabetes, multiple sclerosis, arthritis and many others. Visit for more information about BRI, clinical studies and the more than 80 different types of autoimmune diseases.

Learn the Latest

A sample printed newsletterSign up for our news & updates and learn the latest in the fight against autoimmune diseases.

Sign up today